Trial Profile
A combination immunotherapy for the patients with advanced or metastatic solid cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Jan 2021
Price :
$35
*
At a glance
- Drugs CYT 001 (Primary) ; Eftilagimod alpha (Primary) ; Poly ICLC (Primary)
- Indications Adenocarcinoma; Colorectal cancer; Gastric cancer; Liver cancer; Oesophageal cancer; Pancreatic cancer; Squamous cell cancer
- Focus Adverse reactions; First in man; Proof of concept
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.
- 01 Aug 2020 Results published in the Cancer Immunology Immunotherapy
- 30 Mar 2020 Results published in CYTLIMIC Media Release